Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What would be your post-operative therapy approach for a high grade neuroendocrine carcinoma of the thymus?
What if there was mediastinal nodal involvement?
Answer from: Radiation Oncologist at Academic Institution
Postoperative RT.
Sign in or Register to read more
13071
Related Questions
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?